-
Product Insights
Wind Park N 1
Wind Park N 1 is an Onshore Wind project located in Leningrad, Russia. The project is owned and being developed by WES Sviritsa LLC. The project is at the permitting stage. Empower your strategies with our Wind Park N 1 report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of...
-
Sector Analysis
NewMethicillin-Resistant Staphylococcus aureus (MRSA) Epidemiology Analysis and Forecast to 2033
Methicillin-Resistant Staphylococcus aureus (MRSA) Report Overview In the 7MM, there were 714,131 hospitalized incident cases of Methicillin-Resistant Staphylococcus aureus (MRSA) in 2023. The hospitalized incident cases of Methicillin-Resistant Staphylococcus aureus (MRSA) will register an AGR of more than 1% during 2023-2033. Methicillin-resistant Staphylococcus aureus (MRSA) is a virulent, antibiotic-resistant bacteria that is associated with considerable morbidity and mortality. MRSA can be categorized according to the setting in which the infection was acquired, as either healthcare-associated MRSA (HA-MRSA), which is acquired...
-
Sector Analysis
Non-Small Cell Lung Cancer (NSCLC) Epidemiology Analysis and Forecast to 2032
Non-Small Cell Lung Cancer (NSCLC) Report Overview In the 8MM, there were 1,097,467 diagnosed incident cases of Non-Small Cell Lung Cancer (NSCLC) in 2022. The diagnosed incident cases of Non-Small Cell Lung Cancer (NSCLC) will register an AGR of more than 2% during 2022-2032. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, NSCLC can begin anywhere in the lungs when the healthy cells that make up the lining of the lungs change and grow out...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efruxifermin in Liver Cirrhosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efruxifermin in Liver Cirrhosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efruxifermin in Liver Cirrhosis Drug Details: Efruxifermin (AKR-001) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efruxifermin in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efruxifermin in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efruxifermin in Metabolic Dysfunction-Associated Steatotic Liver Disease...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efruxifermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efruxifermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efruxifermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: Efruxifermin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Blarcamesine Hydrochloride in Infantile Spasm (West Syndrome)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Blarcamesine Hydrochloride in Infantile Spasm (West Syndrome) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Blarcamesine Hydrochloride in Infantile Spasm (West Syndrome) Drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Blarcamesine Hydrochloride in Rett Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Blarcamesine Hydrochloride in Rett Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Blarcamesine Hydrochloride in Rett Syndrome Drug Details: Blarcamesine hydrochloride (ANAVEX-273, AE-37)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Satralizumab in Graves’ Ophthalmopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Satralizumab in Graves' Ophthalmopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Satralizumab in Graves' Ophthalmopathy Drug Details: Satralizumab (Enspryng) is a humanized monoclonal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Satralizumab in Myasthenia Gravis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Satralizumab in Myasthenia Gravis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Satralizumab in Myasthenia Gravis Drug Details: Satralizumab (Enspryng) is a humanized monoclonal...